The total return over the past 12 months is -69.25% vs. +16.94% for the S&P 500. So far it's up -66.48% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (69.25%) | (56.66%) | (59.29%) | (47.32%) | (44.67%) | N/A |
| Total Return CAGR | (69.25%) | (56.66%) | (59.29%) | (47.31%) | (44.67%) | N/A |
| Revenue CAGR | +47.00% | +19.90% | +5.79% | +5.61% | +5.08% | +10.09% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Sonoma Pharmaceuticals, Inc. (SNOA)
| Year | Start price | End price | SNOA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $3.64 | $1.22 | (66.48%) | +14.51% | (80.99%) |
| 2025 | $2.69 | $3.64 | +35.31% | +17.72% | +17.59% |
| 2024 | $3.61 | $2.69 | (25.48%) | +24.89% | (50.37%) |
| 2023 | $22.40 | $3.61 | (83.88%) | +26.19% | (110.07%) |
| 2022 | $91.20 | $22.40 | (75.44%) | (18.17%) | (57.27%) |
| 2021 | $145.20 | $91.20 | (37.19%) | +28.74% | (65.93%) |
| 2020 | $87.20 | $145.20 | +66.51% | +18.37% | +48.14% |
| 2019 | $128.25 | $87.20 | (32.01%) | +31.22% | (63.23%) |
| 2018 | $981.00 | $128.25 | (86.93%) | (4.56%) | (82.37%) |
| 2017 | $907.20 | $981.00 | +8.13% | +21.70% | (13.57%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
